Regeneron, Sanofi Get Expanded FDA OK for Kevzara in Polyarticular Juvenile Idiopathic Arthritis
By Colin Kellaher
Regeneron Pharmaceuticals and Sanofi have won expanded Food and Drug Administration approval of their arthritis drug Kevzara for certain patients with a form of the disease that impacts multiple joints at a time.
Regeneron and Sanofi on Tuesday said the new indication covers the treatment of patients weighing at least 139 pounds who have active polyarticular juvenile idiopathic arthritis.
The companies said the approval adds to Kevzara's position in treating adult chronic inflammatory conditions of moderately to severely active rheumatoid arthritis and polymyalgia rheumatica.
Tarrytown, N.Y., biotechnology company Regeneron and France's Sanofi are jointly developing Kevzara as part of a collaboration that includes the blockbuster anti-inflammatory drug Dupixent.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 11, 2024 07:35 ET (11:35 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Best- and Worst-Performing Stocks of Q2 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations